1910 Genetics and Microsoft partner to enhance pharmaceutical R&D

2024-03-01

Preview

来源: Pharmaceutical Technology

1910’s laboratory automation facility in the Seaport District of Boston, US. Credit: Business Wire/ 1910 Genetics.

1910 Genetics has entered a five-year commercial agreement and go-to-market partnership with Microsoft, aiming to revitalise pharmaceutical research and development (R&D) productivity.

The companies will leverage artificial intelligence (AI) and high-performance computing (HPC) to set up the infrastructure layer for drug discovery and development processes.

The alliance will merge 1910’s computational and wet lab biological information, laboratory automation powered by robotics and multimodal AI models for drug discovery with Microsoft’s Azure Quantum Elements [a new system that aims to accelerate chemical and materials science] and HPC platform.

This process will aid in developing a cloud platform to speed up scientific discovery.

The collaboration will offer access to the platform through three distinct partnership models — co-discovery, co-engineering and platform-as-a-service.

See Also:Jacobio Pharmaceuticals Group sees highest patent filings and grants during October in Q4 2023

Preview

来源: Pharmaceutical Technology

Sihuan Pharmaceutical Holdings Group sees highest patent filings and grants during October in Q4 2023

Preview

来源: Pharmaceutical Technology

These models will serve pharmaceutical, biotechnology, government, academic and research institutions globally.

The collaboration between the companies began in 2021 when M12-Microsoft’s Venture Fund led 1910 Genetics’ Series A financing round securing $22m.

As one of the six Azure Quantum Elements launch customers, and the sole collaborator in the biotech and pharmaceutical industry, 1910’s expanded collaboration with Microsoft will aid in building a foundational infrastructure for pharmaceutical and R&D teams globally.

This infrastructure aims to facilitate and hasten the shift towards AI-driven drug discovery and development, alongside future advancements in drug commercialisation, post-marketing surveillance and real-world evidence analysis.

Microsoft strategic missions and technologies executive vice-president Jason Zander stated: “We are thrilled to be collaborating with 1910 Genetics to bring their pioneering AI drug discovery engines to Azure Quantum Elements.

“This groundbreaking technology holds immense promise for accelerating the design of small and large molecule therapeutics.

“Our collaboration with 1910 Genetics demonstrates our shared commitment to innovation and our aspiration to solve some of the most challenging problems the world faces in drug discovery.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构